The cancer products portfolio that DARA BioSciences (NASDAQ:DARA) has been building by acquisition now has more than $9 million in fresh capital to help bring those products to market. The ...

According to a DARA regulatory filing, Uman is responsible for formulation, analytical and manufacturing work on the drug. Uman must also make the abbreviated new drug application for U.S. marketing ...

DARA BioSciences (Nasdaq: DARA) as the clinical-stage pharmaceutical company acquires the product in a move that positions the company to sell and develop products for the lucrative cancer drug market ...

DARA BioSciences (NASDAQ:DARA), which earlier this week acquired cancer therapeutics firm Oncogenerix, has made yet another deal, this one an agreement to raise $1.7 million in a private placement.

RALEIGH, N.C.--(BUSINESS WIRE)-- DARA BioSciences, Inc. (NAS: DARA) (the "Company" or "DARA") announced that it entered into a definitive securities purchase agreement with certain investors providing ...

Since its approval in 1977, tamoxifen has been used to treat millions of women and men diagnosed with hormone-receptor-positive breast cancer. Treatment with tamoxifen lowers the risk of breast cancer ...